Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis.

Mark A MatzaNicholas DagincourtShalini V MohanAndrey PavlovJian HanJohn H StoneSebastian H Unizony

Published in: RMD open (2023)

Long-term TCZ treatment was associated with remission maintenance in most patients with GCA. The estimated relapse rate by 18 months after TCZ discontinuation was 47.3%.

Keyphrases

giant cell
rheumatoid arthritis
type diabetes
metabolic syndrome
systemic lupus erythematosus
juvenile idiopathic arthritis